Interstitial lung disease due to anti-TNF use in the treatment of psoriasis

AUTOR(ES)

Turíbio, Débora Dorneles Cunha de Queiroz; Oliveira, Francisco Clitson Sousa; Barreto, Sandra Maria Fonseca; Jabour, Thaís Barros Felippe

FONTE

An. Bras. Dermatol.

DATA DE PUBLICAÇÃO

2021-08

RESUMO

Abstract Psoriasis is a chronic inflammatory disease that affects the skin variably, according to genetic and environmental factors. Some patients may benefit from systemic treatment with immunobiological agents, drugs that can be accompanied by several adverse effects. A case of a 58-year-old patient undergoing treatment for psoriasis with adalimumab for five years is reported. Alterations compatible with interstitial pneumonia were detected with important regression after adalimumab discontinuation. This case is relevant due to the scarcity of reports on late pulmonary adverse effect of anti-TNF treatment of psoriasis.

Documentos Relacionados

• Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis
• Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment
• Cutaneous histoplasmosis as a complication after anti-TNF use - Case report
• NICE reviews its guidance against sequential use of anti-TNF drugs for arthritis
• Arterite de Takayasu: tratamento com anti-TNF em uma casuística brasileira